Research Calls I
-
Upgrades:
- Ares Capital (ARCC) upgraded to Overweight from Equal Weight at Wells Fargo; tgt $23
- Embecta Corp. (EMBC) upgraded to Equal-Weight from Underweight at Morgan Stanley; tgt raised to $20
- Globus Medical (GMED) upgraded to Overweight from Equal-Weight at Morgan Stanley; tgt raised to $100
- Intuitive Surgical (ISRG) upgraded to Overweight from Equal-Weight at Morgan Stanley; tgt raised to $650
- LVMH (LVMUY) upgraded to Buy from Hold at HSBC Securities
- NovoCure (NVCR) upgraded to Outperform from In-line at Evercore ISI; tgt raised to $30
- Paycor (PYCR) upgraded to Buy from Hold at TD Cowen; tgt raised to $22
- Stryker (SYK) upgraded to Overweight from Equal-Weight at Morgan Stanley; tgt raised to $445
- Tandem Diabetes Care (TNDM) upgraded to Overweight from Equal-Weight at Morgan Stanley; tgt $45
-
Downgrades:
- AnaptysBio (ANAB) downgraded to Neutral from Buy at BTIG Research
- Bausch + Lomb (BLCO) downgraded to Equal-Weight from Overweight at Morgan Stanley; tgt $19
- Blackstone Secured Lending Fund (BXSL) downgraded to Equal Weight from Overweight at Wells Fargo; tgt $29
- Glaukos (GKOS) downgraded to Underweight from Equal-Weight at Morgan Stanley; tgt $120
- Kering SA (PPRUY) downgraded to Underweight from Neutral at JP Morgan
- Kohl's (KSS) downgraded to Neutral from Buy at Guggenheim
- Markel Group (MKL) downgraded to Hold from Buy at TD Cowen; tgt lowered to $1836
- Nevro (NVRO) downgraded to Underweight from Equal-Weight at Morgan Stanley; tgt lowered to $4
-
Others:
- Block (SQ) named new best idea for 2025 at Bernstein; tgt raised to $120
- BrightView (BV) initiated with a Buy at BTIG Research; tgt $22
- Dominion Energy (D) resumed with a Equal-Weight at Morgan Stanley; tgt $61
- Elanco Animal Health (ELAN) initiated with a Market Perform at Leerink Partners; tgt $14
- IDEXX Labs (IDXX) initiated with a Outperform at Leerink Partners; tgt $500
- PROCEPT BioRobotics (PRCT) initiated with a Overweight at Morgan Stanley; tgt $105
- Voyager Therapeutics (VYGR) initiated with a Buy at Citigroup; tgt $12
- Zoetis (ZTS) initiated with a Outperform at Leerink Partners; tgt $215